The trusted source for
healthcare information and
Treatment helps control involuntary outbursts?
Actions are common in MS, ALS patients
Pseudobulbar affect (PBA) is a neurologic condition of involuntary, sudden, and frequent episodes of laughing or crying and is quite common in patients with underlying neurologic diseases or injuries, especially those with multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS). Now, a new investigational treatment might help stop these involuntary outbursts.
The research was presented as part of the late-breaking science program at the American Academy of Neurology's 62nd Annual Meeting in Toronto in April.
"These outbursts of crying and laughter at inappropriate times can have a severe impact on patient and caregiver well-being, social functioning, and quality of life," said study author Erik P. Pioro, MD, PhD, FRCPC, director of the Section for ALS and Related Disorders at the Cleveland (OH) Clinic.
The study in patients diagnosed with PBA tested the effectiveness of a combination of two medications, dextromethorphan and low dose quinidine. The combination of the drugs is known as DMQ. After completing the blinded, placebo controlled phase of the study, participants could take part in a subsequent open label study where all of the participants would receive the DMQ drug combination for an additional 12 weeks. Of the 283 people completing the first phase, 253, or 89%, chose to take part in this subsequent open label study.
Participants were given daily doses of DMQ and were regularly given a test that measures the frequency and severity of their PBA. The study found that the average test score was significantly improved by 2.7 points from the start to the end of the open label study. Patients who were taking a placebo in the previous clinical trial and switched to DMQ demonstrated the most improvement.
"Our findings represent the first long-term results showing DMQ is effective in helping to control this debilitating condition afflicting patients with neurologic diseases or injuries," said Pioro. "Currently, there are no FDA approved treatments for PBA, which is problematic because currently used off-label treatments are often ineffective or may have unacceptable side effects."
Pioro says these findings, along with additional clinical data, will serve as the basis for an application for FDA approval of DMQ as the first treatment for pseudobulbar affect.
The study was supported by Avanir Pharmaceuticals.